Equities

Rani Therapeutics Holdings Inc

RANI:NMQ

Rani Therapeutics Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.34
  • Today's Change0.03 / 1.30%
  • Shares traded106.15k
  • 1 Year change-15.52%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4998117
Total Receivables, Net------
Total Inventory------
Prepaid expenses2.311.942.14
Other current assets, total--0.50--
Total current assets51101120
Property, plant & equipment, net6.827.104.61
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.25----
Total assets58108124
LIABILITIES
Accounts payable0.651.461.08
Accrued expenses2.393.301.43
Notes payable/short-term debt000
Current portion long-term debt/capital leases4.90--0
Other current liabilities, total0.050.050.13
Total current liabilities7.994.822.64
Total long term debt24290
Total debt29290
Deferred income tax------
Minority interest133774
Other liabilities, total00.060
Total liabilities457177
SHAREHOLDERS EQUITY
Common stock0.010.010.01
Additional paid-in capital867656
Retained earnings (accumulated deficit)(73)(39)(8.33)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.01)(0.07)--
Total equity133747
Total liabilities & shareholders' equity58108124
Total common shares outstanding474949
Treasury shares - common primary issue3.0000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.